Filing Details

Accession Number:
0001209191-24-000369
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-03 16:21:31
Reporting Period:
2023-12-31
Accepted Time:
2024-01-03 16:21:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1787297 Passage Bio Inc. PASG Biological Products, (No Disgnostic Substances) (2836) 822729751
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1922353 S Mark Forman One Commerce Square
2005 Market Street, 39Th Floor
Philadelphia PA 19103
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-31 50,000 $0.00 61,082 No 4 M Direct
Common Stock Disposition 2024-01-02 15,813 $0.91 45,269 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2023-12-31 50,000 $0.00 50,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
Footnotes
  1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
  2. Includes 3,082 shares acquired on May 13, 2022, 4,000 shares acquired on May 15, 2023, and 4,000 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan.
  3. The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
  4. Each RSU represents a contingent right to receive one share of Issuer's common stock.
  5. 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.